6.9 C
Alba Iulia
Thursday, October 1, 2020

Oxford Covid-19 vaccine trial on 510 humans starting Thursday

Must Read

11 best new movies on Netflix: the freshest movies of October 2020

Netflix is ​​giving you the perfect reason to stay this fall. In October, the streaming giant is releasing...

A promotional campaign launched to support Chelsea’s activities

GREENWICH VILLAGE, NY - The Greenwich Village Chelsea Chamber of Commerce is doing its part to bring business back...
LONDON: The Covid-19 vaccine developed by the University of Oxford will be tested on hundreds of humans Great Britain starting Thursday, British Health Secretary Matt Hancock announced Tuesday. “Normally reaching this stage would take years. We will do everything to develop a vaccine, “he said.
A total of 510 healthy volunteers, aged 18 to 55, will participate in the trial. While some participants will receive the vaccine – called ChAdOx1 nCoV-19 – others will take a control injection for comparison. The trial will continue for a few weeks.
The trial, the fourth Covid-19 vaccine to be tested in humans worldwide, will provide valuable insights into the safety aspects of the vaccine, as well as its ability to generate an immune response against the virus.
Coronaviruses have club-shaped spikes on their outer coats. Others’ immune responses coronavirus studies suggest that it is a good target for a vaccine.
The Oxford vaccine contains the genetic sequence of this advanced surface protein inside the construction of the adenovirus vaccine vector (ChAdOx1).
After vaccination, the coronavirus surface protein is produced, which starts the immune system to attack the coronavirus if it later infects the body.
A chimpanzee adenovirus vaccine vector (ChAdOx1) has been chosen as the most suitable vaccine technology for a Covid-19 vaccine because it can generate a strong immune response from a dose and is not a virus replicating, it therefore cannot cause continuous infection in the vaccinated individual.
It also makes it safer to give to children, the elderly and anyone with a pre-existing condition.
Chimpanzee adenoviral vectors have been used safely in thousands of people in vaccines targeting more than 10 different diseases.
In parallel with the completion of the first clinical trial, production of the vaccine is already scaled up for larger trials and, potentially, future deployment.
Dr. Sandy Douglas, who is leading the scale-up, said, “By immediately starting large-scale manufacturing, we hope to accelerate the availability of high-quality safe vaccines.”
The second phase of clinical trials involves raising the maximum age of those receiving the vaccine to over 70 years. The third phase consists of vaccinating 5,000 volunteers over the age of 18, giving half of them the Covid-19 vaccine.
“The best case is that by the fall of 2020, we could have a Phase 3 trial efficacy result to show that the vaccine protects against the virus, as well as the ability to manufacture large quantities of vaccine, but these best- timelines are very ambitious and subject to change, ”said a spokesperson for the vaccine trial at Oxford.
On Tuesday, Hancock awarded the Oxford vaccine project an additional £ 20 million and the Imperial College London project £ 22.5 million. Imperial College has been testing an RNA vaccine candidate in animals since early February. The first discoveries have shown that animals receiving the vaccine are capable of producing neutralizing antibodies against the new coronavirus SARS-CoV-2. The next step is to test whether it can produce the same response in humans.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Latest News

11 best new movies on Netflix: the freshest movies of October 2020

Netflix is ​​giving you the perfect reason to stay this fall. In October, the streaming giant is releasing...

A promotional campaign launched to support Chelsea’s activities

GREENWICH VILLAGE, NY - The Greenwich Village Chelsea Chamber of Commerce is doing its part to bring business back to Lower Manhattan. On Thursday,...

UK manufacturers await the insurance scheme, but still need EU approval

The UK film and TV production restart program will not be open to applications until it has obtained EU state aid approval, a process...

More Articles Like This